s******i
发帖数: 350 | 1 ARIA is partnered with Merck. From phase 3 clinical trial, its new drug
Ponatinib has significant efficacy to treat leukemia. The side effect is
small. The potential market is very promising. | Y****r
发帖数: 3473 | 2 are you talking about APD916 , the chemists that developed it are all laid
off | T*C
发帖数: 5492 | 3 wow...
laid
【在 Y****r 的大作中提到】
: are you talking about APD916 , the chemists that developed it are all laid
: off
| s******i
发帖数: 350 | 4 http://www.news-medical.net/news/20120618/Updated-data-from-ARI
"The pivotal PACE trial data show robust anti-leukaemic activity of
ponatinib in patients with CML at all stages, who are resistant or
intolerant to dasatinib or nilotinib, or who have the T315I mutation, a rare
form of CML which has no available treatment options," said Jane F.
Apperley, professor and chair, Department of Haematology at the Imperial
College, and the chief of service, Clinical Haematology, at the Imperial
College Healthcare NHS Trust, London, England. "Clinical responses to
ponatinib were observed in patients regardless of their mutation status or
disease stage, and the responses appear to be durable, with 93 percent of
chronic-phase CML patients projected to remain in major cytogenetic response
at one year. This clearly highlights the potency of ponatinib."
I am not sure about the info about lay-off. If it is true, I guess it may
not be ponatinib and maybe the company is shifting focus on the new drug
that is going to file NDA with FDA and at the same time laid off non-
promising drug function..
BTW, when and where did you get the layoff info? I am interested to know to
about it.
【在 s******i 的大作中提到】
: ARIA is partnered with Merck. From phase 3 clinical trial, its new drug
: Ponatinib has significant efficacy to treat leukemia. The side effect is
: small. The potential market is very promising.
| s******i
发帖数: 350 | 5 APD916 is made by ARNA (not ARIA).
The stock I mentioned is ARIA. :-)
【在 s******i 的大作中提到】
: ARIA is partnered with Merck. From phase 3 clinical trial, its new drug
: Ponatinib has significant efficacy to treat leukemia. The side effect is
: small. The potential market is very promising.
| s******i
发帖数: 350 | 6 APD916 is from ARNA not ARIA.
laid
【在 Y****r 的大作中提到】
: are you talking about APD916 , the chemists that developed it are all laid
: off
| l********i
发帖数: 2503 | 7 ARIAD expects to file for regulatory approval of ponatinib in the EU and in
the U.S. in Q3 of 2012 based on these clinical data.
在９月３０日前尽量BUY DIP。 | Y****r
发帖数: 3473 | |
|
